Jim Cramer and the CNBC Investing Club discuss the market reaction to President Trump's tariffs on Mexico, Canada, and China. Cramer advises a cautious approach, trimming positions in stocks potentially affected by tariffs. He highlights Abbott and Bristol Myers as potential winners in the pharmaceutical and medical device sectors. The Investing Club takes profits on CrowdeStrike following a recent surge and examines other stocks like Tyson Foods, Becton Dickinson, FedEx, and Nucor.
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. 1. Stocks sold off Monday after President Donald Trump slapped a 25% tariff on Mexico and Canada and 10% on China, to begin on Tuesday. Stocks rapidly cut those losses after Mexican President Claudia Sheinbaum and Trump struck a deal to delay the tariffs for one month.
The company reports this week. 3. Analysts at Baird downgraded cybersecurity stock CrowdeStrike Sunday to neutral from outperform, while its price target to $430 from $390. Analysts warned that expectations might need a reset, which could spell trouble for high-multiple software stocks. We took profits at $403 last week when CrowdeStrike jumped 10% in a software rally driven by hype around Chinese AI startup DeepSeek.
STOCKMARKET TARIFFS CRAMER INVESTING PHARMACEUTICALS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CNBC Investing Club with Jim Cramer: Tuesday RecapThe S&P 500 opened higher but quickly reversed course after strong JOLTS data. Nvidia shares, despite positive news from CES, also reversed sharply lower. Disney, however, bucked the trend, rising modestly following an analyst upgrade.
Read more »
CNBC Investing Club with Jim Cramer: Wednesday's Market RecapJim Cramer reviews Wednesday's market action, highlighting weakness in tech and quantum computing, a positive outlook for GE Healthcare, and his desire to buy more Disney shares.
Read more »
CNBC Investing Club with Jim Cramer: Stocks Sell Off, Home Depot Rallies, Constellation Brands DropsJim Cramer discusses key market movements, including the impact of a strong December jobs report on Fed rate expectations. He also highlights Home Depot's resilience amidst the market downturn and analyzes Constellation Brands' disappointing earnings report.
Read more »
CNBC Investing Club with Jim Cramer: Bristol Myers Squibb, DuPont Spinoff, and AI Chip DemandJim Cramer highlights Bristol Myers Squibb as a potential top stock for 2025, discussing the company's promising schizophrenia drug and other potential applications. DuPont accelerates its spinoff timeline, while Cramer expresses a preference for selling Honeywell shares. Taiwan Semiconductor Manufacturing's strong AI chip revenue projections benefit Club holdings Nvidia and Broadcom.
Read more »
CNBC Investing Club with Jim Cramer: Tuesday Market Recap and Trade RecommendationsJim Cramer and the CNBC Investing Club provide a recap of Tuesday's market action, discussing the impact of President Trump's tariff proposals and making trade recommendations for stocks like Coterra Energy, Honeywell, Eli Lilly, and Abbott Labs.
Read more »
CNBC Investing Club with Jim Cramer: Morning Meeting Recap - January 4, 2023CNBC Investing Club with Jim Cramer recap of key moments from Wednesday's 'Morning Meeting' livestream. Stocks rallied on news of a large AI infrastructure project, boosting tech stocks like Microsoft and Nvidia. Jim Cramer weighs in on the potential of AI, discusses his outlook on various portfolio stocks, including Microsoft, Alphabet, and Disney, and highlights his 'buy' recommendations for Meta and Amazon.
Read more »